INDIVIDUAL MEMBERS

Membership is open to any person working in the pharmacogenomic and personalised medicine field, preferably, but not exclusively, based in a European country.

ESPT individual members have full access to all ESPT activities such as the restricted area on the ESPT web site. They will also benefit from reductions for courses, schools and meetings.

Annual membership fee:

  • 85 €

STUDENTS

Students under 35 years of age, including PhD students, are more than welcome in ESPT!

A special Student membership fee, which gives full access to all ESPT activities such as the restricted area on the ESPT web site as well as reductions for courses, schools and meetings, can be applied when in regular terms of studies.

Annual membership fee for students:

  • 30 €

RESEARCH GROUPS

The strong link between Research Teams, Research Groups working in the field and ESPT represent the scientific image of our organization.

CRITERIA FOR ESPT MEMBERSHIP

ESPT Research groups should represent one or two relevant domains in Pharmacogenomics and Personalized Medicine.

Each group should be constituted by one (or more) leader and 10 to 30 group members.

Group leaders are recognised as full members whilst group members are considered ESPT associate members.

All members, both leaders and associate members, have full access to ESPT activities such as the restricted area on the ESPT web site. They will also benefit from reductions for courses, schools and meetings.

The annual membership fee:

  • 20 € per associate member
  • 85 € for the leader(s)

CURRENT ESPT ACTIVE RESEARCH GROUPS

For more information about the research group, please click on the name of the group.

Name  Location Contact
CANSEARCH research Laboratory Geneva, Switzerland Marc Ansari
Center for Pharmacogenomics – The Ohio State University Columbus, USA Wolfgang Sadee
Extremadura University Hospital and Medical School, Badajoz – CICAB Clinical Research Center Badajoz, Spain Adrian Llerena
Karolinska Institute – Department of Physiology and Pharmacology Stockholm, Sweden Magnus Ingelman-Sundberg
Lab Applied Molecular Biology and Pharmacogenomics – University of Sao Paulo Sao Paulo, Brazil Rosario Hirata
Labex –Institut de Biologie de Lille – CNRS UMR 8199 Lille, France Philippe Froguel
Laboratoire d’hématologie – CHU Timone Marseille, France Pierre Morange / Marie-Christine Alessi
Pharmacogenetics Research Group Rotterdam Rotterdam, The Netherlands Ron H.N. Van Schaik
Pharmacogenomics laboratory – Research Center CHUQ (CHUL) – Laval University Faculty of Pharmacy Quebec, Canada Chantal Guillemette
UMR INSERM U 1122 Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV) Nancy, France Sophie Siest
University of Ljubljana, Faculty of Pharmacy research group Ljubljana, Slovenia Janja Marc

ONGOING DISCUSSIONS

Name Location Contact
Omics Science Center – RIKEN Yokohama Institute Yokohama, Japan Toshihisa Ishikawa
Luxembourg Centre for Systems Medicine Luxembourg Jochen Schneider

Paris Team

Pharmacogénomique des anticoagulants

France Marie-Anne Loriot/ Virginie Siguret / Pascale Gaussem
Charles Auffray Lyon, France Maria Nogueira
Leiden Academic Centre for Drug Research – Leiden University Medical Center Leiden, The Netherlands H.J. Guchelaar/ J.J. Swen
Slovakian Research Group Slovakia Ivan Tkac
IKP Stuttgart – Institut für Klinische Pharmakologie Stuttgart Germany Matthias Schwab
Institute for Pharmacology and Toxicology Center for Pharmacogenetics and Pharmacogenomics – Paracelsus Medical University Salzburg, Austria Markus Paulmichl
Centre Energie Atomique – Saclay Gif sur Yvette, France Isabelle Philippe
Department of Molecular and Clinical Pharmacology – The Wolfson Centre for Personalised Medicine – Institute of Translational Medicine – University of Liverpool Liverpool, United Kingdom Munir Pirmohamed
Department of Neurosciences, Mental Health and Sensory Organs – Sapienza University of Rome Rome, Italy Maurizio Simmaco

NATIONAL SOCIETIES

All National Societies or corresponding networks related to pharmacogenomics that have firmly agreed to collaborate with ESPT in the name of their society can apply for ESPT membership.

CRITERIA FOR ESPT MEMBERSHIP

Each affiliated National Society will be constituted by one national representative and all the members of the society itself.
National representatives are recognised as full members whilst the society members are considered ESPT associate members.
All members, both national representatives and associate members, have full access to ESPT activities such as the restricted area on the ESPT web site. They will also benefit from reductions for courses, schools and meetings.

The annual membership fee:

  • 5 € per associate member
  • 85 € for the national representative

If you wish to become an ESPT affiliated National Society please write an e-mail to office@esptnet.eu.

CURRENT ESPT NATIONAL SOCIETIES

Country Name of the Society Coordinators
Bulgary BAPEMED – Bulgarian Association for Personalized Medicine Gergana Kyosovska
Croatia CSPPT – The Croatian Society of Pharmacogenomics and Personalised Therapy Nada Božina
Denmark DSPM – Danish Society for Personalised Medicine Lona Louring Christrup
Finland FSCP – Finnish Society of Clinical Pharmacology Niemi Mikko
Russia SPPT – Society of Pharmacogenetics, Pharmacokinetics and
Personalized therapy
Denis Fedorinov

CORPORATE MEMBERS

Any company involved in the field of pharmaceutics, biotechnology, laboratory medicine or related disciplines may become a ESPT corporate member.

CRITERIA FOR ESPT MEMBERSHIP

ESPT Corporate Members will be involved in ESPT corporate members meetings to discuss topics of interest and strategy of the Society.

They will be enlisted in the dedicated area of the ESPT web site and they will also benefit from special fees at ESPT events (National Congresses as well as Summer Schools).

Corporate membership is €1.500 per year with a minimum of 2 years subscription.

Companies can apply for ESPT membership by writing an e-mail to
office@esptsociety.eu.

COLLABORATIONS

European Institutional collaborators
We are cooperating with the following European Institutional members to avoid overlapping and to reinforce the translation of Pharmacogenomics into clinical practice.

Name   Contact
EFLM – European Federation of Clinical Chemistry and Laboratory Medicine      Mauro Panteghini
EPHAR – Federation of European Pharmacological Societies   Thomas Griesbacher
ESF – European Science Foundation   Kirsten Steinhausen
EDMA – European Diagnostic Manufacturers Association   Serge Bernasconi
EUSPM – European Society of Predictive Medicine   Maurizio Ferrari

 

We are in discussion with:

EHA -European Association of Hematologists   Christine Chomienne
EFPIA – European Federation of Pharmaceutical Industries and Associations      Magda Chlebus
ESCP – European Society of Clinical Pharmacy   Olivier Bourdon/J. Swen
EACPT – European Association for Clinical Pharmacology and Therapeutics   Simon Tabassome
EAPM – The Europe Alliance for Personalised Medicine   Denis Horgan
EUPATI – European Patients Academy   Ingrid Klingmann

We have also good contacts with other European organizations particularly:

Name   Contact
EMA – European Medicines Agency      Marisa Papaluca
IMI –Innovative Medicines Initiative Magda Gunn
ESHG – European Society of Human Genetics   Jerome del Picchia
ESBB – European, Middle Eastern and African Society for Biopreservation and Biobanking   Robert Hewitt
EPEMED – European Personalized Medicine Association   Alain Huriez
EUFEPS – European Federation for Pharmaceutical Sciences   Meindert Danhof

 

International Institutional collaborators

We are cooperating with the following International Institutional members to avoid overlapping and to reinforce the translation of Pharmacogenomics into clinical practice:

Name      Contact
IFCC – International Federation of Clinical Chemistry and Laboratory Medicine   Maurizio Ferrari
IUPHAR – International Union of Basic and Clinical Pharmacology – Pharmacogenomics Subgroup   Guilherme Kurtz-Suarez

We have also good contacts with other International organisations particularly:

Name     Contact
ISSX – International Society for the Study of Xenobiotics   John Miners
IATDMCT – International Association of Therapeutic Drug Monitoring and Clinical Toxicology   Pierre Wallemacq
ISNN – International Society of Nutrigenetics/Nutrigenomics   Alfredo Martinez
FIP – International Pharmaceutical Federation   Bernard Poggi